Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Authors:

Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M MD, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka AP, Ferreri AJM, Merli F, Zhao WL, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens KS, Ielmini N, De Martino I, Walewski J, Trněný M, Cavalli F, Ricardi U, Johnson PWM, Davies AJ, Martelli M.

Source:

Blood

This website only uses technical cookies and does not collect personal data or use profiling cookies. By continuing to browse, you accept the use of cookies.